Drug compounds targeting 4 of these 19 genes have been in phase II or III clinical trials and include PSMB4 (rated as high confidence level in our findings) for glioblastoma multiforme (2 drugs, phase III), P2RX7 (high confidence level) for rheumatoid arthritis and osteoarthritis (3 drugs, phase II), and CACNA2D2 (high confidence level) for generalized anxiety disorder, fibromyalgia, and neuropathic pain (3 drugs, phase III), and EPHB2 (moderate confidence level) for thyroid carcinoma (phase IV)50 (Supplementary Table 18). Secondary analyses of those and future compounds undergoing clinical investigations would likely prove valuable to test the hypothesis that these proteins play a causal role in development of depression.
